Good day, everyone, and welcome to Nuwellis’ Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. Please note this call may be recorded. I'll be standing by if you should need any assistance. It is now my pleasure to turn the program over for forward-looking statements, Vivian Cervantes, Investor Relations.

Thank you. Good morning everyone and welcome to Nuwellis’ earnings conference call for the third quarter ended September 30, 2024. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter ended September 30, 2024. In addition to myself, with us today are Nestor Jaramillo, Nuwellis' President and CEO, Dr. John Jefferies, our Chief Medical Officer; as well as Rob Scott, our CFO. At 8 a.m. Eastern Time today, Nuwellis released financial results for the third quarter 2024. If you have not received Nuwellis' earnings release, please visit the investors page on the company's website. During today's call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends as well as our estimated results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filing through the Securities and Exchange Commission, including the latest 10-K. With that, I now would like to turn the call over to Nestor.

Thank you, Vivian, and good morning, everyone. Welcome to Nuwellis third quarter 2024 earnings conference call. On today's call, I will provide an overview of our third quarter performance and give an update on our strategic initiatives, followed by Dr. Jefferies, our Chief Medical Officer, who will provide a summary of the recent publication on the efficacy of Nuwellis in a real-world community hospital setting. Our Chief Financial Officer, Rob Scott, will then provide detailed commentary on our financial results before opening up the call for questions, followed by my closing remarks. Nuwellis generated $2.4 million in revenue for the third quarter of 2024, a 2% decrease year-over-year. However, sequentially, we grew 8% over Q2. While the adult category of our business saw a lower volume of patients treated during the summer months, our pediatric customer category experienced a surge in revenue of 28% compared to the same quarter of last year, driven by three new pediatric accounts opened this quarter, including one of the largest hospital networks in Florida. We also experienced a sequential improvement in pediatric census. In addition to the pediatric account, we also opened two additional adult accounts. We are excited to continue to drive market penetration of our differentiated Aquadex ultrafiltration therapy as we leverage our body of clinical evidence. For the remainder of our customer category, critical care and heart failure were down 25% and 36% respectively on lower consumables utilization and console sales, reflecting the generally lower volume of patients treated during the summer months. One of our key initiatives for the last three years has been to build our body of clinical evidence in order to make this therapy standard of care and get into the medical society guidelines. In support of this initiative, I would like now to turn it over to Dr. Jefferies to discuss the latest addition to our growing body of clinical evidence and the impact that this clinical information may have in broad day-to-day clinical practice. Dr. Jefferies?

Thank you, Nestor, and good morning, everyone. In August, we announced the publication of a new study in current problems in cardiology, demonstrating the effectiveness of Aquadex in significantly reducing 60-day hospital readmission rates for patients with acutely decompensated heart failure who were otherwise resistant to diuretic treatment in a community hospital setting. As the senior author on this paper, I was pleased to see the analysis of an Aquadex program in community-based regional hospitals showing how refractory acute decompensated heart failure patients benefited from significant volume loss and weight reduction along with stable renal function and remarkable clinical benefit. I would like to highlight that the outcomes of this community-based hospital setting trial demonstrate the broader applicability and effectiveness of the Aquadex therapy. Real-world data in some ways is often more powerful than randomized controlled trials because it uses everyday patients that need to be treated rather than a cohort of preselected patients which typically occurs as a certain group of academic institutions. The outcome of this study shows that ultrafiltration can be very effective for these real-world types of patients. This is vital for Nuwellis’ strategy as we now have the data to leverage as we expand the use of this therapy to these hospitals in a non-academic center setting. Going deeper into the study's findings, it showed that favorable Aquadex therapy programs can result early, as shown in this hospital system in the form of reduced acute decompensated heart failure readmissions. There are numerically fewer 30-day acute decompensated heart failure readmissions after Aquadex program initiation compared to pre-program initiation with a statistical p-value of 0.351. However, at 60 days, there were significantly fewer acute decompensated heart failure readmissions with a statistically significant p-value of 0.013. Additionally, patients experienced significant volume reduction with a mean fluid loss of 9.4 liters and a significant weight loss with a mean decrease of 7.4 kilograms. Notably, all 30 patients had stable renal function and no significant change in serum creatinine, a test used to measure kidney function after 72 hours of ultrafiltration therapy. Finally, the study had important practical implications for heart failure clinics, demonstrating that a successful Aquadex program is reproducible and can be coordinated by general cardiologists without the need for a dedicated heart failure unit. We continue to enroll patients in the reverse HF trial, which is designed to help increase awareness and provide the data to support becoming standard of care. The study has enrolled over one-third of the patients contemplated by the protocol. I welcome any questions on this new evidence during the Q&A session. And now, I'd like to turn to Rob to discuss our third quarter financial results.

Thank you, Dr. Jefferies, and good morning, everyone. Turning to the Q3 financial results, revenue for the third quarter was $2.4 million, representing an 8% sequential growth and a 2% decline over the prior year period. Our pediatric customer category surged with a 28% increase compared to a year ago as we expanded our Aquadex offerings to three new pediatric centers, one of which is within one of the largest hospital networks in Florida. Our critical care and heart failure customer categories were down 25% and 36% year-over-year respectively. These declines are due to lower consumables utilization in the summer months and also because of console sales. Gross margin was 70% for the third quarter compared to gross margin of 57.3% in the prior year quarter. The margin improvement was primarily driven by higher manufacturing volumes of consumables and lower fixed overhead manufacturing expenses. Selling, general and administrative expenses were $2.7 million in the third quarter, a decrease of approximately 21% as compared to $3.4 million in the third quarter of 2023. The decrease in SG&A was primarily realized through efficiency initiatives enacted in the second half of 2023. Third quarter research and development expense was $486,000 compared to $1.1 million in the prior year period. The decrease in R&D expense was primarily due to reduced consulting fees and compensation-related expenses. Total operating expenses were $3.2 million in the quarter, a decrease of approximately $1.4 million or 30% as compared to the third quarter of 2023 as we continue to realize savings from operating efficiency initiatives enacted in the second half of 2023. Operating loss in the third quarter was $1.5 million compared to an operating loss of $3.2 million in the prior year period, resulting in a $1.7 million period-over-period improvement. Net income attributable to common shareholders in the third quarter was $2.4 million or a gain of $1.74 per share compared to a net loss attributable to common shareholders of $3.4 million or a loss of $63.27 per share for the same period in 2023. Third quarter net income improvement was primarily the result of the revaluation of a prior period warrant liability resulting in a $3.9 million benefit. We ended the third quarter with $1.9 million in cash and cash equivalents and with no debt on the balance sheet. Our cash balance in the third quarter includes the August and July registered direct offerings priced at the market under NASDAQ rules, with gross proceeds of approximately $892,000 and $2 million respectively. As we previously disclosed, we mutually terminated our license and distribution agreement with SeaStar Medical, resulting in a settlement in October whereby they agreed to pay Nuwellis $900,000 by the end of the calendar year. We received approximately $500,000 in the month of October. This concludes our prepared remarks. Operator, we would now like to open the call to questions.

We'll take a question from Jonathan Aschoff of Roth. Your line is open.

Thank you, guys. Good morning. I would like to ask you to walk us through an economic comparison of the now profitable, given the heightened reimbursement. The now profitable way that hospitals can use Aquadex in the outpatient setting, and the money they would make versus the money they would make doing ultrafiltration a different way for these same outpatients?

Very good question, Jonathan. This may take a little longer, this explanation. Right now, the only way that ultrafiltration is provided is in the inpatient setting. Patients get hospitalized, and it takes anywhere from three to five days to remove the fluid off these patients. If you consider the reimbursement structure, there are three DRGs that reimburse the inpatient treatment of heart failure. Any one of those three DRGs, the hospital incurs a loss because the cost of a patient to be treated for heart failure for decompensated heart failure in the hospital is about $24,000, and the highest DRG is probably $12,000. So the hospital incurs a loss. With this reimbursement, now the hospitals can provide ultrafiltration in the outpatient setting. It could be in an observation unit or even in the ER. And the patient doesn't need to be admitted to the hospital. Secondly, the reimbursement now is $1,639 per day. So if the patient needs three days to remove the fluid that the physician recommends, then it would be that amount every day. So the hospital now, given our cost of the circuit, which is $900, can make $700 a day for treating these patients. Again, the patient can take anywhere from three days treating the patient, coming in and out of the observation unit. Therefore, the hospital would have more profits from the therapy.

Right, so you would see this totally replacing the inpatient population for those that don't have to be there for some other reason?

Right. We envision that this could replace admitting the patient in the hospital, decongesting the patient in the ER or in the observation unit, thereby avoiding the need to admit the patient in the ICU or hospital for ultrafiltration.

Okay, so then, I mean, is there any difference in actual outpatient medical benefit between these two procedures, meaning Aquadex versus some sort of dialysis machine they might use? Because as long as the hospital can justify doing no harm, it's always going to make more money if it can.

Correct. We believe that treating patients with decompensated heart failure in the outpatient setting would be more profitable for the hospitals. I forgot to mention one other aspect of treating patients in the inpatient setting. If the patient is readmitted within 30 days, then the hospital doesn't get paid by CMS or most private payers and also incurs some penalties. So that's another savings because the patient was not admitted. In terms of the patient, the benefit to the patient, it is well documented that patients that get hospitalized, regardless of the condition, experience higher mortality rates. By not having to be admitted, patients are not exposed to those high mortality risks. Additionally, the treatment would only take anywhere from four to six hours, and after that, the patient can just go home and then schedule the next visit. For the patient, this would be much better, ensuring also a better quality of life.

Okay, so then, what's the crux of what went wrong with DaVita, why that never matured into what it was hoping to mature into?

Yeah, Jonathan, that's a good question. We have internally debated the reasons for this. When we started the conversations with DaVita, we had a champion in that organization. As soon as we signed the agreement, that champion got promoted, and then we were assigned a different team, causing us to lose a bit of momentum. Also, at the beginning, we did not target the right centers. We targeted centers that were good customers of Nuwellis and they were happy treating the patients by their staff in the inpatient setting. They did not need the DaVita personnel. We then pivoted and targeted accounts familiar with ultrafiltration who faced issues with capital, budgets, and personnel. However, it just took too long for them to get ready to use ultrafiltration provided by DaVita.

All right. Thanks. Also, when can we expect the reverse HF trial data? I'm sorry, I had concomitant calls, so maybe you said something about timelines and enrollment percent already, and if you did, would you please reiterate that?

Right. At the current rate of enrollment, we expect to finish the enrollment period by the middle of 2026. After that, there is a 90-day follow-up, and then we would have the data analyzed and be ready to submit by the end of 2026.

Okay, you mean to the FDA?

Correct. Well, not to the FDA; I’m sorry, not to the FDA. To submit publications and to submit to the medical societies for them to include this therapy in the guidelines, assuming we expect the results to be very favorable.

And did you give an update for Vivian's progress?

Yes, we continue the development phase of Vivian, and we're estimating that by the end of 2025, we will be ready to start the in-human clinical study. It will be an IDE trial, which will be an FDA trial, and we have already agreed on the protocol with the FDA.

Thank you very much, Nestor.

Thank you, Jonathan.

We'll move next to Anthony Vendetti of Maxim Group.

Thanks, good morning. So these new rates which are substantially higher for ultrafiltration go into effect 01/01/25, correct? And how are you internally preparing the organization to capitalize on this in all three phases, pediatric, critical care, and heart failure? Specifically, how are you addressing this with your customers? What's the go-forward plan?

Good question and good morning, Anthony. First of all, we're very excited about this new assigned code that triples the reimbursement. We are preparing by identifying those hospitals, those centers, those accounts that used to do ultrafiltration in the outpatient setting. Back in 2012, there were about 12 centers that were doing ultrafiltration in the outpatient setting. It requires a setup. It requires patients to be able to come in, sit down in the chair, and then get the ultrafiltration therapy performed. Also, they need to set up what is called the order set, and we have to ensure that those hospitals in those territories have coverage from either local CMS administrators and also private payers. So we're getting ready on both helping the hospitals get set up as well as making sure that the reimbursement is ready to be filed.

Okay, do you feel like at this point you have all the personnel you need in place or do you believe that with this higher reimbursement, you may hire a couple of either clinical people or sales people to try to accelerate the adoption?

Yeah, good question. Right now, we have nine territories in place with sales reps and clinical specialists so we can start with those areas. Most of these hospitals that were doing ultrafiltration in the outpatient setting in the past have not been covered. So we would not need to add anyone in the field to get started with outpatient ultrafiltration. We are going to look into bringing some expertise when it comes to reimbursement inside the headquarters.

Okay, great. Thank you very much. I'll hop back into the queue. Appreciate it.

It seems we have no further questions for now. I would like to hand the conference back to our hosts for any final comments.

Thank you, operator. We continue to see momentum in our business with new accounts steadily opening on increasing awareness of the efficacy and supporting clinical evidence for Aquadex ultrafiltration in the adult and pediatric customer categories. We believe these clinical results, as described by Dr. Jefferies, will have a positive impact in growing our business and supporting Aquadex in becoming the standard of care for fluid removal when diuretics are ineffective. As we reported early last week, we were pleased to announce the company received the notice from the Center of Medicare and Medicaid Services, also known as CMS, that the Aquadex ultrafiltration code will be reassigned to the outpatient reimbursement level, most consistent with the administration of ultrafiltration therapy and cost of treatment. So, effective January 1, 2025, the facility reimbursement fee will increase 297% from $413 to $1,639 per day. With this increased reimbursement, we are opening a new chapter for Nuwellis. We anticipate seeing accelerated top-line growth from this rate increase. Additionally, as reported early last week, the company raised $5.1 million in gross proceeds from warrant exercises and through a warrant inducement solicitation. I want to thank all the stakeholders, Nuwellis employees, stockholders, physicians, nurses, and patients, and healthcare workers in the field. Without your support, we would not be able to achieve key advances in transforming the lives of patients suffering from fluid overload. Thank you for your participation and support.

This does conclude Nuwellis’ third quarter 2024 earnings conference call. You may now disconnect your lines and everyone have a great day.